FOLFIRI Regimen with or without Bevacizumab As Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

#1743

Introduction: Metastatic disease of GEP-NEC is tough condition in clinical practice. And the role of the second-line therapy remains unknown

Aim(s): To explore efficacy and safety of FOLFIRI ± BEV in 2nd treatment

Materials and methods: Eleven GEP-NEC patients were treated with FOLFIRI regimen ± BEV after failure of first-line chemotherapy between July 2014 and June 2016 in our center. Data including clinical and pathological parameters were collected at the time of diagnosis and during treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: ZHIYU C

Authors: Chen Z, Zhao X, Wang C, Zhang W, Zhu X,

Keywords: NEC, FOLFIRI, bevacizumab ,